866-997-4948(US-Canada Toll Free)

Global Cystic Fibrosis Therapeutics Market 2016-2020

Published By :

Technavio

Published Date : Oct 2016

Category :

Cardiovascular Devices

No. of Pages : 80

About Cystic Fibrosis

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

Technavios analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
F. Hoffmann-La Roche
Gilead Sciences
Novartis
Vertex Pharmaceuticals

Other prominent vendors
Advanced Inhalation Therapies (AIT)
Alaxia SAS
Alcresta Therapeutics
AlgiPharma
Allergan
Anthera
AstraZeneca
Bayer
Celtaxsys
Chiesi Farmaceutici
Corbus Pharmaceuticals
Cyclacel Pharmaceuticals
Digestive Care
Galapagos
Grifols
Insmed Incorporated
Kamada
Nivalis Therapeutics
Novoteris
Parion Sciences
Pharmaxis
ProQR Therapeutics
Protalix Biotherapeutics
Proteostasis Therapeutics
PTC Therapeutics
Pulmatrix
Savara
SolAeroMed
Vectura

Market driver
Special regulatory designations for drugs
For a full, detailed list, view our report

Market challenge
Discontinuation of drugs from development
For a full, detailed list, view our report

Market trend
Co-pay and assistance programs by vendors
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.





PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Pathophysiology
Diagnosis
Manifestations of cystic fibrosis
PART 06: Pipeline analysis
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by drug class
CFTR modulators
Mucolytics
PERT
Anti-infectives
Bronchodilators
PART 09: Market segmentation by molecule type
Small molecules
Biologics
PART 10: Geographical segmentation
Global cystic fibrosis therapeutics market by geography
Cystic fibrosis therapeutics market in Americas
Cystic fibrosis therapeutics market in EMEA
Cystic fibrosis therapeutics market in APAC
PART 11: Key leading countries
The US
The UK
France
Canada
Italy
PART 12: Market drivers
Special regulatory designations for drugs
Increased uptake of CFTR modulators
Improvement in diagnostic technologies
PART 13: Impact of drivers
PART 14: Market challenges
Discontinuation of drugs from development
Difficulty in developing drugs due to rarity of disease
PART 15: Impact of drivers and challenges
PART 16: Market trends
Co-pay and assistance programs by vendors
Strategic collaborations
Advances in technology for drug development and delivery
PART 17: Vendor landscape
Competitive scenario
Other prominent vendors
PART 18: Key vendor analysis
Vertex Pharmaceuticals
F. Hoffmann-La Roche
AbbVie
Gilead Sciences
Novartis
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for global cystic fibrosis therapeutics market 2015
Exhibit 03: Key customer segments of cystic fibrosis therapeutics market
Exhibit 04: Snapshot of cystic fibrosis
Exhibit 05: Defects caused by CFTR mutation
Exhibit 06: Diagnosis of cystic fibrosis
Exhibit 07: Pipeline portfolio: Global cystic fibrosis therapeutics market
Exhibit 08: Global cystic fibrosis therapeutics market: Market overview 2015
Exhibit 09: Global cystic fibrosis therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Global cystic fibrosis therapeutics market 2015-2020 ($ billions)
Exhibit 11: Opportunity analysis: Global cystic fibrosis therapeutics market
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Five forces analysis
Exhibit 14: Global cystic fibrosis therapeutics by drug class 2015
Exhibit 15: Global cystic fibrosis therapeutics market by molecule type 2015
Exhibit 16: Global cystic fibrosis therapeutics market by geography 2015-2020
Exhibit 17: Percentage share of global cystic fibrosis therapeutics market by geography 2015 and 2020
Exhibit 18: Global cystic fibrosis therapeutics market by geography 2015-2020 ($ billions)
Exhibit 19: Global share of cystic fibrosis therapeutics market by geography 2015
Exhibit 20: Global cystic fibrosis therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 21: Global cystic fibrosis therapeutics market: Country analysis based on revenue and growth rate
Exhibit 22: Opportunity analysis: Cystic fibrosis therapeutics market in Americas
Exhibit 23: Cystic fibrosis therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis: Cystic fibrosis therapeutics market in EMEA
Exhibit 25: Cystic fibrosis therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 26: Opportunity analysis: Cystic fibrosis therapeutics market in APAC
Exhibit 27: Cystic fibrosis therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 28: Key leading countries for cystic fibrosis therapeutics market
Exhibit 29: Impact of drivers and challenges on global cystic fibrosis therapeutics market
Exhibit 30: Few drugs with breakthrough therapy designation for cystic fibrosis
Exhibit 31: Drugs with orphan drug designation for cystic fibrosis
Exhibit 32: Impact of drivers
Exhibit 33: Few cystic fibrosis therapeutics discontinued from development
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Global cystic fibrosis therapeutics market: Impact assessment of key trends
Exhibit 36: Few cystic fibrosis therapeutics with patient assistance programs
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors 2015
Exhibit 39: Competitive scenario of market vendors 2015-2020
Exhibit 40: Vertex Pharmaceuticals: Profile
Exhibit 41: Vertex Pharmaceuticals: Strength analysis
Exhibit 42: Vertex Pharmaceuticals: Growth strategy matrix
Exhibit 43: Vertex Pharmaceuticals: Opportunity assessment
Exhibit 44: Vertex Pharmaceuticals: Revenue of ORKAMBI and Kalydeco 2015 ($ millions)
Exhibit 45: F. Hoffmann-La Roche: Profile
Exhibit 46: F. Hoffmann-La Roche: Strength analysis
Exhibit 47: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 48: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 49: F. Hoffmann-La Roche: YoY growth and revenue generated from sales of Pulmozyme 2013-2015 ($ millions)
Exhibit 50: AbbVie: Profile
Exhibit 51: AbbVie: Strength analysis
Exhibit 52: AbbVie: Growth strategy matrix
Exhibit 53: AbbVie: Opportunity assessment
Exhibit 54: AbbVie: YoY growth and revenue of Creon 2013-2015 ($ millions)
Exhibit 55: Gilead Sciences: Profile
Exhibit 56: Gilead Sciences: Strength analysis
Exhibit 57: Gilead Sciences: Growth strategy matrix
Exhibit 58: Gilead Sciences: Opportunity assessment
Exhibit 59: Novartis: Profile
Exhibit 60: Novartis: Strength analysis
Exhibit 61: Novartis: Growth strategy matrix
Exhibit 62: Novartis: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *